Skip to Content
Cancer Imaging Program (CIP)
Contact CIP
Show menu
Search this site
Last Updated: 03/22/23

Programs & Resources

Program Project (P01) Grant Development Guidance for Investigators Interested in DCTD Research Areas

  • The goal of this guidance is to help investigators navigate through the P01 (Program Project Grant) pre-application process in the cancer research areas that DCTD supports.
  • The Cancer Imaging Archive (TCIA) is provided by the Cancer Imaging Program (CIP) as a service to the research community. TCIA provides a freely accessible, open archive of cancer-specific medical images and metadata accessible for public download. A huge amount of clinical and research images are collected each year with many high value data sets already available. TCIA organizes and catalogs the images so that they may be used for a variety of purposes.
  • NCI-supported research resource network promoting quantitative imaging therapeutic or prevention co-clinical trials with patients and human-in-mouse models.
  • The NCI Alliance for Nanotechnology in Cancer is an integrated, milestone driven, and product oriented program aimed at eliminating the burden of cancer. Committed to building a community of researchers dedicated to using nanotechnology to advance the fight against cancer, the Alliance is engaged in efforts to harness the power of nanotechnology to radically change the way we diagnose, treat, and prevent cancer. The Alliance works in concert with other NCI advanced technology initiatives to provide the scientific foundation and team science that is required to transform cancer research and care.

The CIP IND Directory is a centralized resource to facilitate the sharing of IND information. If you have an IND for an imaging agent, you are welcome to provide some or all of the following information to for inclusion in the directory:

  • Agent Name (required)
  • IND# (posting the IND# is optional, but you must confirm that an approved IND is in place)
  • Contact Institution (required)
  • Contact (you may provide a direct email address, refer to a publication, or have inquiries directed to CIP)
  • Source DOC Issue Date (year of publication, or investigator communication with CIP)
  • Source Documentation (publications that refer to IND, or other investigator communications)
  • (NCT numbers for clinical trials associated with your IND agent)
  • Synonyms (optional)
  • The Cancer Imaging Program has been creating Investigational New Drug Applications (IND) for imaging agents in order to engage in multi-center clinical trials of these materials. A subset of the documents filed is being made available to the research community to implement routine synthesis of tracers at their own facilities and to assist investigators with the filing of their own INDs. The document sets available are for F-18 fluorothymidine (FLT), F-18 FMISO, and F-18 FES.
  • Cancer may be difficult to detect, but for some types of cancer, the earlier it is detected, the better are the chances of treating it effectively. Imaging techniques — methods of producing pictures of the body — have become an important element of early detection for many cancers.

Additional Resources

The NExT Program is designed to advance clinical practice and bring improved agents to cancer patients by supporting promising drug discovery and development. The NExT Program is a resource, not a grant mechanism. Applications with exceptional drug and imaging agent development proposals that have a clear path to clinical use and will be of potential benefit to patients are accepted. For awardees, the NCI may allocate resources for evaluation and development of submitted projects. The NCI will partner with successful applicants to facilitate milestone-driven development of new anticancer drugs (small molecules, biologics) and imaging agents through the required steps towards clinical evaluation and registration.

The NCI-Frederick Small Animal Imaging Program was established to provide NCI Investigators with a state-of-the-art In Vivo imaging facility. It has been operational since October 2006. Capabilities include optical imaging, ultrasound, magnetic resonance imaging and positron emission tomography and access to a range of appropriate contrast agents.

NCI is contributing to the global effort to address COVID-19 by mobilizing its scientific experts and cutting-edge resources to conduct research on the SARS-CoV-2 virus, which causes COVID-19. This research includes studies of antibodies to the virus, how the virus affects cancer patients, and factors that influence disease severity.